Abstract
A variant of the SIR model for an inhomogeneous population is introduced in order to account for the effect of variability in susceptibility and infectiousness across a population. An initial formulation of this dynamics leads to infinitely many differential equations. Our model, however, can be reduced to a single first-order one-dimensional differential equation. Using this approach, we provide quantitative solutions for different distributions. In particular, we use GPS data from ∼ 107 cellphones to determine an empirical distribution of the number of individual contacts and use this to infer a possible distribution of susceptibility and infectivity. We quantify the effect of ℛ0 superspreaders on the early growth rate 0 of the infection and on the final epidemic size, the total number of people who are ever infected. We discuss the features of the distribution that contribute most to the dynamics of the infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors acknowledge the generous support of Chan Zuckerberg Initiative and Chan Zuckerberg Biohub. M. Rychnovsky is partially supported by Ivan Corwin's NSF grant DMS:1811143 as well as the Fernholz Foundation's "Summer Minerva Fellows" program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Theoretical model only, no oversight necessary
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Not applicable
